Cartesian Therapeutics, Inc.
RNAC Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$6.28
KIRA · Stoqly’s AI analyst, in plain words
- Cartesian Therapeutics, Inc. had $2.8M of revenue in fiscal 2025, down 92.8% on the year before. Over five years, revenue changed −30.0% a year on average.
- Its operating margin was −5,127.1%, down 5,014.3 pts: of every 100 in sales, about −5,127 is left after running the business.
- Cartesian Therapeutics, Inc. lost $130M in fiscal 2025.
- Free cash flow was −$79.4M in fiscal 2025, −2,838.6% of revenue.
- Cartesian Therapeutics, Inc. has $125M more cash than debt.
Market cap
$188M
P/E
—
Revenue
$2.8M
Net income
−$130M
Free cash flow
−$79.4M
Operating margin
−5,127.1%
Cartesian Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−92.8%
No. Sales fell 92.8% last year.
Does it make a profit?
−4,658.6%
No. It lost money last year.
Does profit turn into cash?
−2,838.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cartesian Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- Cartesian Therapeutics, Inc.
- CIK
- 0001453687
Cartesian Therapeutics, Inc. · RNAC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $85.1M | $111M | $26.0M | $38.9M | $2.8M |
| Revenue growth | 412.6% | 30.2% | −76.5% | 49.6% | −92.8% |
| Operating margin | −5.4% | 13.1% | −332.3% | −112.8% | −5,127.1% |
| Net income | −$25.7M | $35.4M | −$220M | −$77.4M | −$130M |
| Net margin | −30.2% | 31.9% | −844.9% | −199.0% | −4,658.6% |
| Diluted EPS | −$0.22 | $0.10 | −$49.76 | −$4.49 | −$5.02 |
| Cash | |||||
| Cash from operations | −$60.4M | −$31.6M | −$51.2M | −$23.7M | −$73.9M |
| Capital expenditure | $1.1M | $1.2M | $0.2M | $9.1M | $5.5M |
| Free cash flow | −$61.5M | −$32.8M | −$51.4M | −$32.8M | −$79.4M |
| FCF margin | −72.2% | −29.6% | −197.5% | −84.2% | −2,838.6% |
| Share count change | 13.0% | 27.6% | −96.5% | 235.7% | 49.6% |
| Debt and strength | |||||
| Cash and short-term investments | $128M | $135M | $76.9M | $213M | $125M |
| Debt incl. finance leases | — | — | — | — | $0.0M |
| Shareholders' equity | $22.5M | $93.8M | −$440M | −$6.8M | −$126M |
| Current ratio | 2.0x | 5.9x | 1.3x | 9.4x | 8.7x |
| Interest coverage | −1.6x | 4.8x | −30.5x | — | — |
| Returns and quality | |||||
| Return on equity | −1,137.9% | 60.8% | — | — | — |
| Return on tangible equity | −114.1% | 37.7% | — | — | — |
| Piotroski F-score | 3 | 4 | 2 | 4 | 1 |
| Altman Z'' | −5.8 | −0.9 | −9.0 | −3.0 | −10.1 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.3M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cartesian Therapeutics, Inc. · RNAC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.28 a share, the company is worth $188M.
Source: SEC EDGAR XBRL filings (CIK 0001453687). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.